Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting clinical trials

Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure

This study is testing a new way to treat liver cancer (HCC) using two medications, Durvalumab and Tremelimumab, before and after a procedure to remove the cancer. We want to see if this combination is safe and effective for people with early-stage HCC.